These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31202564)

  • 1. Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.
    Grottke O; Braunschweig T; Rossaint R; Akman N; Leeds JM; Conley PB; Honickel M
    Br J Anaesth; 2019 Aug; 123(2):186-195. PubMed ID: 31202564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
    Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
    PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical safety and efficacy of andexanet alfa in animal models.
    Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
    J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
    Bourdin M; Perrotin D; Mathieu O; Herve T; Depasse F; Lu G; Conley PB; Contant G
    Int J Lab Hematol; 2021 Aug; 43(4):795-801. PubMed ID: 34092030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexanet Alfa: First Global Approval.
    Heo YA
    Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andexanet: Effectively Reversing Anticoagulation.
    Lippi G; Sanchis-Gomar F; Favaloro EJ
    Trends Pharmacol Sci; 2016 Jun; 37(6):413-414. PubMed ID: 27048885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
    Powell J; Taylor J; Garland SG
    Ann Pharmacother; 2019 Sep; 53(9):940-946. PubMed ID: 30813754
    [No Abstract]   [Full Text] [Related]  

  • 11. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
    Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
    Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
    Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
    Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
    Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
    N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
    Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
    Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.